The Middle East & Africa Checkpoint Inhibitors Market size has been valued at USD 1.28 billion in 2022. It is further expected to reach USD 4.28 billion by 2027, growing at a CAGR of 27.19 % during the forecast period.
Checkpoint inhibitors are cancer medicines that target the checkpoints. As a result, the market for checkpoint inhibitors is expected to grow as cancer incidence rates rise.
The checkpoint inhibitors market in this region is expected to be driven by the Y-O-Y rise in the various types of malignancies and the increase in the geriatric population in the Middle East and Africa, particularly in the market and rising economies. In addition, during the forecast period, the rise in the number of cancer cases in MEA is expected to accelerate the growth of the checkpoint inhibitors market in this region. Lung, prostate, bowel, and female breast cancer are the four most frequent kinds of cancer, accounting for 34 percent of all new cancer cases.
Increased cancer prevalence in the Middle East and Africa demand for ideal therapeutics for cancer treatment, favorable reimbursement policies offered by manufacturers and insurance providers in some countries, and increased awareness of checkpoint inhibitors for cancer treatment due to positive results are a few key factors driving the growth of the Middle East and Africa checkpoint inhibitors market.
However, the checkpoint inhibitor market in the MEA region is projected to be hampered by the high cost of cancer therapy using checkpoint inhibitors. There's a lot of pressure to keep costs low and demonstrate value. In addition, political uncertainty and ongoing economic stress are putting public health care funding in jeopardy in several countries. The lack of cost-effective cancer medicines has influenced the population's health and resulted in poor life expectancy. The drop is primarily due to the outbreak, which has resulted in tight containment measures such as social distancing, remote working, and the closure of industries and other commercial operations, all of which have impacted market growth.
This research report on the Middle East and Africa checkpoint inhibitors market has been segmented and sub-segmented into the following categories.
By Drug:
By Application:
By Country:
Geographically the Middle East and Africa are projected to register a moderate share of the global checkpoint inhibitors market during the forecast period. However, the UAE is predicted to have the largest market share in MEA from 2022 to 2027. During the forecast period, the presence of a large population of baby boomers in UAE necessitated the efficient treatment of various chronic diseases such as diabetes, skin cancer, urothelial carcinomas, Diabetes, skin cancer, urothelial carcinomas, and lung cancers are all on the rise, as is the prevalence of numerous chronic diseases like diabetes, skin cancer, urothelial carcinomas, and lung cancers.
KEY MARKET PLAYERS:
Some of the key companies leading the Middle East & Africa Checkpoint Inhibitors Market are Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Type
5.1.1 Introduction
5.1.2 PD-1 inhibitors
5.1.3 PD-L1 inhibitors
5.1.4 CTLA-4
5.1.5 Chimeric Antigen Receptor T-cell
5.1.6 Others
5.1.7 Y-o-Y Growth Analysis, By Drug Type
5.1.8 Market Attractiveness Analysis, By Drug Type
5.1.9 Market Share Analysis, By Drug Type
5.2 Application
5.2.1 Introduction
5.2.2 Lung cancer
5.2.3 Renal cancer
5.2.4 Blood cancer
5.2.5 Bladder Cancer
5.2.6 Hodgkin lymphoma
5.2.7 Melanoma
5.2.8 Others
5.2.9 Y-o-Y Growth Analysis, By Application
5.2.10 Market Attractiveness Analysis, By Application
5.2.11 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Drug Type
6.1.3.3 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Drug Type
6.1.4.3 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Drug Type
6.1.5.3 By Application
6.2 Middle-East
6.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Merck & Co., Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Bristol-Myers Squibb
8.3 Roche
8.4 AstraZeneca
8.5 Ono Pharmaceutical Co., Ltd.
8.6 Juno Therapeutics
8.7 Novartis International AG
8.8 Kite Pharma
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
